Top

Published in:

01-08-2020 | Ulcerative Colitis | Review

Is Parkinson’s disease a chronic low-grade inflammatory bowel disease?

Authors: Malvyne Rolli-Derkinderen, Laurène Leclair-Visonneau, Arnaud Bourreille, Emmanuel Coron, Michel Neunlist, Pascal Derkinderen

Published in: Journal of Neurology | Issue 8/2020

Abstract

While the pathogenesis of Parkinson’s disease is not fully understood, there is increasing evidence that inflammatory responses in the brain are implicated in both disease initiation and progression. The inflammatory process in Parkinson’s disease is, however, not limited to the brain but also involves the gastrointestinal tract. High amounts of cytokines and inflammatory markers are found in the colon of Parkinson’s disease patients and there is now strong epidemiological and genetical evidence linking Parkinson’s disease to inflammatory bowel diseases. Recent findings obtained in both experimental inflammatory bowel diseases and Parkinson’s disease further support a bidirectional link between gastrointestinal inflammation and brain neurodegeneration. Altogether, these observations suggest a role for gastrointestinal inflammation in the initiation and progression of Parkinson’s disease.

Chapelet G, Leclair-Visonneau L, Clairembault T et al (2018) Can the gut be the missing piece in uncovering PD pathogenesis? Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2018.11.014 CrossRefPubMed

Edwards LL, Quigley EM, Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 42:726–732CrossRef

Beach TG, Adler CH, Sue LI et al (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119:689–702. https://doi.org/10.1007/s00401-010-0664-3 CrossRefPubMedPubMedCentral

Gelpi E, Navarro-Otano J, Tolosa E et al (2014) Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 29:1010–1018. https://doi.org/10.1002/mds.25776 CrossRefPubMed

Wakabayashi K, Takahashi H, Takeda S et al (1988) Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 76:217–221CrossRef

Bialecka M, Kurzawski M, Klodowska-Duda G et al (2007) CARD15 variants in patients with sporadic Parkinson’s disease. Neurosci Res 57:473–476. https://doi.org/10.1016/j.neures.2006.11.012 CrossRefPubMed

Maeda S, Hsu L-C, Liu H et al (2005) Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science 307:734–738. https://doi.org/10.1126/science.1103685 CrossRefPubMed

Umeno J, Asano K, Matsushita T et al (2011) Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 17:2407–2415. https://doi.org/10.1002/ibd.21651 CrossRefPubMed

Hui KY, Fernandez-Hernandez H, Hu J et al (2018) Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aai7795 CrossRefPubMedPubMedCentral

10.

Bihari K, Lees AJ (1987) Cigarette smoking, Parkinson’s disease and ulcerative colitis. J Neurol Neurosurg Psychiatry 50:635CrossRef

11.

Fujioka S, Curry SE, Kennelly KD et al (2017) Occurrence of Crohn’s disease with Parkinson’s disease. Parkinsonism Relat Disord 37:116–117. https://doi.org/10.1016/j.parkreldis.2017.01.013 CrossRefPubMed

12.

Lin J-C, Lin C-S, Hsu C-W et al (2016) Association between parkinson’s disease and inflammatory bowel disease: a Nationwide Taiwanese Retrospective Cohort Study. Inflamm Bowel Dis 22:1049–1055. https://doi.org/10.1097/MIB.0000000000000735 CrossRefPubMed

13.

Peter I, Dubinsky M, Bressman S et al (2018) Anti-tumor necrosis factor therapy and incidence of parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2018.0605 CrossRefPubMedPubMedCentral

14.

Villumsen M, Aznar S, Pakkenberg B et al (2018) Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977–2014. Gut. https://doi.org/10.1136/gutjnl-2017-315666 CrossRefPubMed

15.

Weimers P, Halfvarson J, Sachs MC et al (2019) Inflammatory bowel disease and Parkinson’s disease: a Nationwide Swedish Cohort Study. Inflamm Bowel Dis 25:111–123. https://doi.org/10.1093/ibd/izy190 CrossRefPubMed

16.

Zhu F, Li C, Gong J et al (2019) The risk of Parkinson’s disease in inflammatory bowel disease: a systematic review and meta-analysis. Dig Liver Dis 51:38–42. https://doi.org/10.1016/j.dld.2018.09.017 CrossRefPubMed

17.

Marras C, Lang AE, Austin PC et al (2016) Appendectomy in mid and later life and risk of Parkinson’s disease: a population-based study. Mov Disord 31:1243–1247. https://doi.org/10.1002/mds.26670 CrossRefPubMed

18.

Mendes A, Gonçalves A, Vila-Chã N et al (2015) Appendectomy may delay Parkinson’s disease onset. Mov Disord 30:1404–1407. https://doi.org/10.1002/mds.26311 CrossRefPubMed

19.

Palacios N, Hughes KC, Cereda E et al (2018) Appendectomy and risk of Parkinson’s disease in two large prospective cohorts of men and women. Mov Disord 33:1492–1496. https://doi.org/10.1002/mds.109 CrossRefPubMedPubMedCentral

20.

Yilmaz R, Bayram E, Ulukan Ç et al (2017) Appendectomy history is not related to Parkinson’s disease. J Parkinsons Dis 7:347–352. https://doi.org/10.3233/JPD-171071 CrossRefPubMed

21.

Svensson E, Horváth-Puhó E, Stokholm MG et al (2016) Appendectomy and risk of Parkinson’s disease: a nationwide cohort study with more than 10 years of follow-up. Mov Disord 31:1918–1922. https://doi.org/10.1002/mds.26761 CrossRefPubMed

22.

Killinger BA, Madaj Z, Sikora JW et al (2018) The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aar5280 CrossRefPubMedPubMedCentral

23.

Altschuler SM, Escardo J, Lynn RB, Miselis RR (1993) The central organization of the vagus nerve innervating the colon of the rat. Gastroenterology 104:502–509CrossRef

24.

Gray MT, Munoz DG, Gray DA et al (2014) Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord 29:991–998. https://doi.org/10.1002/mds.25779 CrossRefPubMed

25.

Russel MG, Dorant E, Brummer RJ et al (1997) Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 113:377–382CrossRef

26.

Devos D, Lebouvier T, Lardeux B et al (2013) Colonic inflammation in Parkinson’s disease. Neurobiol Dis 50:42–48. https://doi.org/10.1016/j.nbd.2012.09.007 CrossRefPubMed

27.

Pochard C, Leclair-Visonneau L, Coron E et al (2018) Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson’s disease. Mov Disord 33:493–494. https://doi.org/10.1002/mds.27237 CrossRefPubMed

28.

Perez-Pardo P, Dodiya HB, Engen PA et al (2018) Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice. Gut. https://doi.org/10.1136/gutjnl-2018-316844 CrossRefPubMed

29.

Eeckhaut V, Machiels K, Perrier C et al (2013) Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut 62:1745–1752. https://doi.org/10.1136/gutjnl-2012-303611 CrossRefPubMed

30.

Houser MC, Chang J, Factor SA et al (2018) Stool immune profiles evince gastrointestinal inflammation in Parkinson’s disease. Mov Disord 33:793–804. https://doi.org/10.1002/mds.27326 CrossRefPubMedPubMedCentral

31.

Schwiertz A, Spiegel J, Dillmann U et al (2018) Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2018.02.022 CrossRefPubMed

32.

Eichele DD, Kharbanda KK (2017) Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterol 23:6016–6029. https://doi.org/10.3748/wjg.v23.i33.6016 CrossRefPubMedPubMedCentral

33.

Villarán RF, Espinosa-Oliva AM, Sarmiento M et al (2010) Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson’s disease. J Neurochem 114:1687–1700. https://doi.org/10.1111/j.1471-4159.2010.06879.x CrossRefPubMed

34.

Garrido-Gil P, Rodriguez-Perez AI, Dominguez-Meijide A et al (2018) Bidirectional neural interaction between central dopaminergic and gut lesions in Parkinson’s disease models. Mol Neurobiol. https://doi.org/10.1007/s12035-018-0937-8 CrossRefPubMed

35.

Blandini F, Armentero M-T, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2):S124–S129. https://doi.org/10.1016/j.parkreldis.2008.04.015 CrossRefPubMed

36.

Pellegrini C, Fornai M, Colucci R et al (2016) Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. J Neuroinflamm 13:146. https://doi.org/10.1186/s12974-016-0608-5 CrossRef

37.

Zheng L-F, Wang Z-Y, Li X et al (2011) Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson’s disease. Brain Res 1420:59–67. https://doi.org/10.1016/j.brainres.2011.09.006 CrossRefPubMed

38.

Lema Tomé CM, Tyson T, Rey NL et al (2013) Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease—is there a link? Mol Neurobiol 47:561–574. https://doi.org/10.1007/s12035-012-8267-8 CrossRefPubMed

39.

Houser MC, Tansey MG (2017) The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinsons Dis 3:3. https://doi.org/10.1038/s41531-016-0002-0 CrossRefPubMedPubMedCentral

40.

Walter GC, Phillips RJ, Baronowsky EA, Powley TL (2009) Versatile, high-resolution anterograde labeling of vagal efferent projections with dextran amines. J Neurosci Methods 178:1–9. https://doi.org/10.1016/j.jneumeth.2008.11.003 CrossRefPubMed

41.

Liu B, Fang F, Pedersen NL et al (2017) Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology 88:1996–2002. https://doi.org/10.1212/WNL.0000000000003961 CrossRefPubMedPubMedCentral

42.

Svensson E, Horváth-Puhó E, Thomsen RW et al (2015) Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol 78:522–529. https://doi.org/10.1002/ana.24448 CrossRefPubMed

43.

Prigent A, Lionnet A, Durieu E et al (2019) Enteric alpha-synuclein expression is increased in Crohn’s disease. Acta Neuropathol 137:359–361. https://doi.org/10.1007/s00401-018-1943-7 CrossRefPubMed

44.

Prigent A, Gonzales J, Durand T et al (2018) Acute inflammation down-regulates alpha-synuclein expression in enteric neurons. J Neurochem. https://doi.org/10.1111/jnc.14656 CrossRef

45.

Guan Q, Zhang J (2017) Recent advances: the imbalance of cytokines in the pathogenesis of inflammatory bowel disease. Mediat Inflamm 2017:4810258. https://doi.org/10.1155/2017/4810258 CrossRef

46.

Fedorova TD, Seidelin LB, Knudsen K et al (2017) Decreased intestinal acetylcholinesterase in early Parkinson disease: an 11C-donepezil PET study. Neurology 88:775–781. https://doi.org/10.1212/WNL.0000000000003633 CrossRefPubMed

47.

Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49:328–338. https://doi.org/10.1111/ejn.14094 CrossRefPubMed

48.

Johnson ME, Stecher B, Labrie V et al (2019) Triggers, facilitators, and aggravators: redefining Parkinson’s disease pathogenesis. Trends Neurosci 42:4–13. https://doi.org/10.1016/j.tins.2018.09.007 CrossRefPubMed

49.

Zou W, Pu T, Feng W et al (2019) Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein. Transl Neurodegener 8:7. https://doi.org/10.1186/s40035-019-0147-y CrossRefPubMedPubMedCentral

50.

Takagawa T, Kitani A, Fuss I et al (2018) An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aan8162 CrossRefPubMedPubMedCentral

Title: Is Parkinson’s disease a chronic low-grade inflammatory bowel disease?
Authors: Malvyne Rolli-Derkinderen
Laurène Leclair-Visonneau
Arnaud Bourreille
Emmanuel Coron
Michel Neunlist
Pascal Derkinderen
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keywords: Ulcerative Colitis
Crohn's Disease
Chronic Inflammatory Bowel Disease
Parkinson's Disease
Appendectomy
Published in: Journal of Neurology / Issue 8/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09321-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is Parkinson’s disease a chronic low-grade inflammatory bowel disease?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Correction to: Optical coherence tomography shows neuroretinal thinning in myelopathy of adrenoleukodystrophy

Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers

Correction to: Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study

Moyamoya angiopathy: radiological follow-up findings in Finnish patients

Correction to: Endovascular stroke treatment’s impact on malignant type of edema (ESTIMATE)

The IN-DEEP project “INtegrating and Deriving Evidence, Experiences, Preferences”: a web information model on magnetic resonance imaging for people with multiple sclerosis